ProMIS Neurosciences to Participate in Upcoming Conferences in June

ProMIS Neurosciences (Nasdaq: PMN) will participate in several healthcare and biotech conferences in June 2026, including Jefferies, Wolfe Research’s Virtual Alzheimer’s R&D Day, Oppenheimer CNS Summit, H.C.

Rhea-AI Summary

ProMIS Neurosciences (Nasdaq: PMN) will participate in several healthcare and biotech conferences in June 2026, including Jefferies, Wolfe Research’s Virtual Alzheimer’s R&D Day, Oppenheimer CNS Summit, H.C. Wainwright Neuro Perspectives, and BIO International.

CEO Neil Warma will present the EpiSelect™ platform, lead Alzheimer’s candidate PMN310, and timelines for PRECISE-AD Phase 1b data.

Argus May 28 session

+3.77% close to close Open Argus

Details

News Market Reaction – PMN

On May 28, the day this news came out, PMN closed 3.77% above the previous close.

Data tracked by StockTitan Argus for the May 28 session.

Key Figures

Interim data timing: 6-month blinded interim data Topline data timing: 12-month topline data Jefferies conference slot: 11:40 a.m.–12:10 p.m. ET +5 more

Interim data timing

6-month blinded interim data

PRECISE-AD Phase 1b in early Q3 2026

Topline data timing

12-month topline data

PRECISE-AD Phase 1b anticipated early 2027

Jefferies conference slot

11:40 a.m.–12:10 p.m. ET

June 4, 2026 Jefferies Global Healthcare Conference

Alzheimer’s R&D Day slot

8:30 a.m.–9:00 a.m. ET

June 4, 2026 Virtual Alzheimer’s R&D Day

Conference window

June 2–25, 2026

Series of five conferences across NY, Miami, San Diego

Trial phase

Phase 1b

PRECISE-AD trial in early Alzheimer’s disease

Share price level

$10.48

Pre-news price vs. 52-week range $6.27–$39.75

ATM capacity

$50,000,000

ATM program under S-3 shelf registration

Historical Context

5 past events · Latest: May 12

5 events

1. May 12

   Q1 results & funding

   24h Move

   -1.8%

   Reported Q1 2026 results, PIPE financing up to $175M and cash runway through 2027.

2. Apr 13

   Investor conference

   24h Move

   +2.5%

   Invitation to Bloom Burton investor conference and update on PRECISE-AD Phase 1b timelines.

3. Mar 25

   FY 2025 results

   24h Move

   -9.1%

   Full-year 2025 results, completed PRECISE-AD enrollment and $75.5M upfront financing for runway.

4. Mar 18

   Scientific data posters

   24h Move

   -13.0%

   AD/PD 2026 posters on ALS and Parkinson’s vaccine and antibody programs targeting misfolded proteins.

5. Feb 04

   Biotech summit participation

   24h Move

   -16.3%

   Participation in Guggenheim biotech summit with fireside chat and one-on-one investor meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1b, amyloid-beta oligomers, biomarker, disease modifying therapies, +1 more

5 terms

phase 1b medical

"PRECISE-AD Phase 1b trial in patients with early AD in early Q3 2026"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

amyloid-beta oligomers medical

"PMN310 is designed to selectively target toxic amyloid-beta oligomers believed to drive AD pathology"

Amyloid-beta oligomers are small, sticky clumps of a protein fragment that can build up in the brain and interfere with how nerve cells communicate, often linked to cognitive decline. They matter to investors because drugs or tests that can reduce, block or detect these clumps are central to many neurological drug development and diagnostic strategies, and progress or setbacks in that area can strongly affect the value and prospects of companies working on related therapies.

biomarker medical

"a blinded 6-month safety and biomarker interim analysis is planned"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

disease modifying therapies medical

"discussing the current treatment landscape, development of disease modifying therapies and symptom management"

Therapies that change the underlying course of a disease rather than only treating symptoms; they aim to slow, halt, or reverse the biological processes causing decline, like fixing a car’s engine instead of repeatedly patching the exhaust. Investors care because success can transform long-term patient need, pricing power, market size and regulatory value, so these treatments often carry higher rewards and higher clinical and approval risk than symptom-only drugs.

webcast technical

"Webcast replays of the presentations will be available in the Investors section"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.

Conference details below:

Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.

Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from 8:30 a.m. to 9:00 a.m. ET (invitation-only)
The event will feature leading companies and key opinion leaders in Alzheimer’s disease research, discussing the current treatment landscape, development of disease modifying therapies and symptom management.

Oppenheimer CNS Summit, June 10, 2026
Location: Miami, FL
One-on-one meetings only

H.C. Wainwright Neuro Perspectives Expert Summit, June 15-16, 2026
Location: New York, NY
Presentation: Monday, June 15, 2026

BIO International Convention, June 22-25, 2026
Location: San Diego, CA
One-on-one meetings only

During these conferences, Neil Warma, CEO of ProMIS Neurosciences, will discuss the Company’s EpiSelect™ platform and differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins, including its lead Alzheimer’s disease (AD) candidate, PMN310.

PMN310 is designed to selectively target toxic amyloid-beta oligomers believed to drive AD pathology while avoiding plaque binding, an approach intended to potentially reduce off-target effects associated with plaque-directed therapies.

ProMIS expects to report blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in early Q3 2026, with 12-month topline data anticipated in early 2027.

Webcast replays of the presentations will be available in the Investors section of the ProMIS Neurosciences website at https://www.promisneurosciences.com/ under “News & Events”.

About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

Forward-looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the ‎use of forward-looking terminology such as “plans”, “expects”, “anticipates”, “believes”, or variations of such words and ‎phrases. Specifically, this news release contains forward-looking information relating to the Company’s Phase 1b study in AD patients, including planned timing for completion and anticipated data read out of interim results expected in early third quarter of 2026 and topline results by early 2027, statements relating to the Company's progress, including enrollment and dosing, the potential for PMN310 to positively benefit patients with AD, the targeting of toxic misfolded proteins, and the ability of the Company’s cash runway to fund operations through 2027. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to ‎known and unknown risks and uncertainties, including the risk that preclinical results or early results may not be indicative of future results. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information.

Investor Relations Contact:
Carie Pierce VP, Investor Relations & External Affairs
IR@promisneurosciences.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which June 2026 conferences will ProMIS Neurosciences (PMN) attend?

ProMIS Neurosciences plans to attend multiple June 2026 events, including Jefferies Global Healthcare, Wolfe Research’s Virtual Alzheimer’s R&D Day, Oppenheimer CNS Summit, H.C. Wainwright Neuro Perspectives Expert Summit, and the BIO International Convention, according to ProMIS Neurosciences.

When is ProMIS Neurosciences presenting at the Jefferies Global Healthcare Conference 2026 (PMN)?

ProMIS Neurosciences is scheduled to present at Jefferies Global Healthcare Conference on Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET. According to ProMIS Neurosciences, the event will take place in New York, with a webcast link made available.

What will ProMIS Neurosciences discuss about PMN310 at June 2026 conferences?

ProMIS Neurosciences plans to discuss its lead Alzheimer’s candidate PMN310, which is designed to selectively target toxic amyloid-beta oligomers while avoiding plaque binding. According to ProMIS Neurosciences, this approach is intended to potentially reduce off-target effects seen with plaque-directed therapies.

When will ProMIS Neurosciences report PRECISE-AD Phase 1b data for PMN310 (PMN)?

ProMIS Neurosciences expects to report blinded 6-month interim data from the fully enrolled PRECISE-AD Phase 1b trial in early Q3 2026. According to ProMIS Neurosciences, 12-month topline data are anticipated in early 2027 for patients with early Alzheimer’s disease.

How can investors access ProMIS Neurosciences’ June 2026 conference webcasts and replays?

Investors can access webcast replays of ProMIS Neurosciences’ June 2026 presentations in the Investors section of the company’s website. According to ProMIS Neurosciences, replays will be available under the “News & Events” area at its official site.

What topics will ProMIS Neurosciences cover at Wolfe Research’s Virtual Alzheimer’s R&D Day 2026?

At Wolfe Research’s Virtual Alzheimer’s R&D Day on June 4, 2026, ProMIS Neurosciences will present from 8:30 a.m. to 9:00 a.m. ET. According to ProMIS Neurosciences, the event features discussions on current Alzheimer’s treatments, disease-modifying therapies, and symptom management.

Who will represent ProMIS Neurosciences at June 2026 conferences and what platform will be highlighted?

CEO Neil Warma will represent ProMIS Neurosciences at the June 2026 conferences. According to ProMIS Neurosciences, he will highlight the company’s EpiSelect™ platform and differentiated approach to targeting toxic misfolded proteins in neurodegenerative diseases, including Alzheimer’s disease candidate PMN310.